Amneal stock: buy or sell?

AMRX stock price: $3.05 0.66% At close on April 2nd, 2020

Updated on:
April 2nd, 2020


After sliding a bloodcurdling -14.85% yesterday, Amneal closed today at $3.05 and grew a tiny 0.66%. On Mar/31 AMRX skyrocketed an extraordinary 11.78%.

Should I buy Amneal stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

None of our preferred buy setups matches with Amneal stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean AMRX will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Amneal Pharmaceuticals stock a buy?

Banks and financial institutions post stock ratings everyday. Unfortunately, we couldn't find any rating for AMRX stock for the last 30 days.

Amneal stock analysis

Daily outlook

After sliding a bloodcurdling -14.85% yesterday, Amneal closed today at $3.05 and grew a tiny 0.66%.

After sliding a bloodcurdling -14.85% yesterday, Amneal closed today at $3.05 and grew a tiny 0.66%. Since March/20 when SMA100d and SMA200d crossed up, AMRX price slipped $-0.14 per share (-4.39%). AMRX is retaking the upward trend marking a new rising bottom heading to break out over $4.38.

AMRX stock chart (daily)

Weekly outlook

After sliding a chilling -19.00% in a week last week, Amneal closed this week at $3.05 and grew a good 1.67%. By mid March AMRX boosted an outstanding 15.13% in just one week.

Since SMA20w and SMA40w crossed up early March, AMRX price slid a -20.78%. Since price and 40-weeks moving average lines crossed down late February, AMRX fell $-1.60 per share (-34.41%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average line is not recommended by many experts, as it indicates that the stock has not enough institutional support.

AMRX stock chart (weekly)

Amneal stock price history

Amneal IPO was on May 7th, 2018 at $17.00 per share1. Since then, AMRX stock declined a -82.10%, with a yearly average of -82.10%.

1: Adjusted price after possible price splits or reverse-splits.

Amneal stock historical price chart

AMRX stock reached 52-week highs at $14.65, and all-time highs 2018-08-22 with a price of 24.48.

Amneal stock price target

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we have not detected any price prediction for Amneal Pharmaceuticals stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

Since May, when Amneal presented its last earnings report, it . As soon as we get its posted EPS from the earnings report, we will extend this review.
AMRX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual sales report draw an exceptional increase of 60.89% to $1,662.99 M USD. When comparing 2018 vs 2017, nevertheless, profit margin (that is, the net income divided by revenues) slightly fell a -1.26% to -1.26%.

To have an updated picture of the financial situation of Amneal Pharmaceuticals, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual Amneal Pharmaceuticals TTM sales up to were $1,387.80 and earnings were $-20.92 million dollars. If we compare this TTM figures with the last reported annuality, we can esteem Amneal business evolution since December 2018: Annual revenues up to , compared to lastest yearly report, plummed a spooky -16.55%. Nevertheless, profit margin (net income/revenues) stayed constant at -1.26%.

AMRX annual Sales and Income evolution
2013$512 M-$101 M19.8%-
2014$596 M16.53%$57 M9.6%-43.36%
2015$860 M44.36%$39 M4.5%-32.00%
2016$1,018 M18.33%$0.00 M0.0%-100.00%
2017$1,034 M1.52%$0.00 M0.0%0.00%
2018$1,663 M60.89%$-20.92 M-1.3%0.00%
TTM $1,388 M-16.55%$-20.92 M-1.5%0.00%

Quarterly financial results

Amneal Pharmaceuticals posted million in sales for 2019-Q1, a -100.00% decline compared to previous quarter. Reported quarter income marked million with a profit margin of . Profit margin remained steady a 0.00% compared to previous quarter when profit margin was -1.76%. When comparing revenues to same quarter last year, Amneal sales marked a neutral movement and stayed stable a nan%.
AMRX quarterly Sales and Income evolution
2017-Q1$184 M-$-98.43 M-53.4%-
2017-Q2$260 M40.93%$37.45 M14.4%-138.04%
2017-Q3$255 M-1.98%$0.00 M0.0%-100.00%
2017-Q4$183 M-28.20%$-301.07 M-164.6%0.00%
2018-Q2$414 M126.22%$-19.10 M-4.6%-93.65%
2018-Q3$476 M15.15%$6.95 M1.5%-136.39%
2018-Q4$498 M4.42%$-8.77 M-1.8%-226.12%

Amneal ownership

When you are planning to buy shares of a company, it's always worth to check its ownership structure.

Amneal shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 12.76% of all shares.

In case of Amneal stock, 69.48% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AMRX stock account 0.00%, no big difference from last month.

For a better understanding, the next table shows ownership data compared to other related companies:

Market cap$449.3 M
Total shares147.3 M
Float shares94.4 M
  - Institutional holdings (%)69.5%
  - Insider holdings (%)12.8%
Shares in short selling0.0%

Amneal summary

Thursday, April 2nd, 2020
Day range$2.91 - $3.18
Previous close$3.03
Session gain0.66%
Average true range$0.52
50d mov avg$4.01
100d mov avg$4.06
200d mov avg$3.85
Daily patternlb02a
Weekly pattern lt03a

Amneal performance

To measure stock performance is always good to compare with competitors or related stocks. We compared Amneal against in the following table:
AMRXAmneal Pharmaceut...-35.38%-3.79%-78.37%

Amneal competitors

Unfortunately, we could not find any public company that could be defined as Amneal Pharmaceuticals competitor. This doesn't mean Amneal Pharmaceuticals does not have any competitor in the market, it's just we could not detected it.